# US 8,278,054 B2 · Diagnosis of metal allergy through cytokine release by T-cells in vitro

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,054 B2
- Document ID: US8278054B2
- Status: Granted
- Kind: B2
- Application number: 10/471,479
- Filed: 2002-03-12
- Published: 2004-06-17
- Granted: 2012-10-02
- Earliest claimed: 2001-03-12
- Assignees: Mabtech AB
- Inventors: Eva Jakobson
- Web page: https://patentgrep.com/patent/US8278054B2

## CPC

- G01N 33/6869: {Interleukin}
- G01N 33/505: {involving T-cells}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 2333/5406: IL-4
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An in vitro method for diagnosing a contact allergy in a subject comprises: (i) providing (a) a contact allergen; (b) T-cells from said subject; and (c) a surface to which is immobilized a first specific binding agent capable of specifically binding to a cytokine released from a T-cell in response to said allergen; (ii) contacting said sample with said allergen under conditions which are suitable for (a) release of said cytokine by T cells that have been presensitized in vivo to said allergen; and (b) binding of said cytokine to said first specific binding agent; and (iii) detecting binding of said substance to said first specific binding agent. A kit which enables the method to be carried out is also described.

## Claims

### Claim 1

An in vitro method for diagnosing a nickel allergy in a subject, which method comprises:
(i) providing
(a) a solution comprising a nickel salt;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to said nickel salt wherein said cytokine is selected from the group consisting of IL-4, IL-5, and IL-13;
(ii) contacting said T-cells with said nickel salt, said antigen presenting cells and said surface under conditions which are suitable for
(a) release of said cytokine by said T-cells that have been presensitized in vivo to nickel by skin contact of the subject with said nickel; and
(b) binding of said cytokine to said first antibody to form a cytokine/antibody complex; and
(iii) detecting binding of said cytokine to said first antibody, by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting said cytokine, thereby detecting any nickel-specific T-cells at the single cell level which have been presensitized by skin contact of the subject with said nickel, where the detection of said presensitized T-cells secreting IL-4, IL-5, IL-13 or a combination thereof, correlates with said nickel allergy.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said nickel salt is a solution of NiCl2 or NiSO4.

### Claim 3 (depends on 1)

A method according to claim 1 wherein said spots are detected using a second antibody which specifically binds to said cytokine.

### Claim 4 (depends on 3)

A method according to claim 3 wherein said second antibody is labeled.

### Claim 5 (depends on 1)

A method according to claim 1 wherein said T-cells which are secreting two or more of said cytokines are detected.

### Claim 6

An in vitro method for diagnosing a skin contact allergy to nickel in a subject, which method comprises:
(i) providing
(a) a solution comprising a nickel salt;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to said nickel salt, wherein said cytokine is selected from the group consisting of IL-4, IL-5, and IL-13;
(ii) contacting said T-cells with said solution, said antigen presenting cells and said surface under conditions which are suitable for
(a) release of said cytokine by said T-cells that have been presensitized in vivo to said nickel by skin contact of the subject with the said nickel; and
(b) binding of said cytokine to said first antibody to form a cytokine/antibody complex; and
(iii) detecting binding of said cytokine to said first antibody by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting said cytokine, thereby detecting nickel-specific T-cells at the single cell level which have been presensitized by skin contact of the subject with said nickel, where the detection of the presensitized T-cells secreting IL-4, IL-5, IL-13, or a combination thereof, correlates with said contact allergy to nickel.

### Claim 7

An in vitro method for diagnosing nickel allergy in a subject, which method comprises:
(i) providing
(a) a nickel salt;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to said nickel salt, wherein said cytokine is selected from the group consisting of IL-4, IL-5 and IL-13;
(ii) contacting said T-cells with said nickel salt, said antigen presenting cells and said surface under conditions which are suitable for
(a) release of said cytokine by said T-cells that have been presensitized in vivo to nickel and
(b) binding of said cytokine to said first antibody to form a cytokine/antibody complex; and
(iii) detecting binding of said cytokine to said first antibody, by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting said cytokine, thereby detecting nickel-specific T-cells at the single cell level, where said spots are enumerated using a second antibody which is labeled and which specifically binds to said cytokine and where the detection of the presensitized T-cells secreting IL-4, IL-5, IL-13, or a combination thereof, correlates with said nickel allergy.

### Claim 8

An in vitro method for determining whether a subject has an allergy against nickel, where the allergy is caused by contact of the skin of said subject with said nickel, which method comprises:
(i) providing
(a) a solution comprising said nickel;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to said nickel wherein said cytokine is selected from the group consisting of IL-4, IL-5, and IL-13;
(ii) contacting said T-cells with said nickel, said antigen presenting cells and said surface under conditions which are suitable for:
(a) release of said cytokine by said T-cells that have been presensitized in vivo to said nickel; and
(b) binding of said cytokine to said first antibody to form a cytokine/antibody complex;
(iii) detecting binding of said cytokine to said first antibody by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting said cytokine, thereby detecting cytokine releasing T-cells at the single cell level; and
(iv) comparing the results of (iii) with those of a control performed without said nickel, where if the number of said cytokine releasing T-cells is greater in (iii) than for the control, the subject is determined to have an allergy against nickel.

### Claim 9

An in vitro method for determining whether a subject has an allergy against nickel, where the allergy is caused by contact of the skin of said subject with said nickel, said method being carried out in a microtitre plate, with assays using an antibody against different cytokines being performed in separate wells of said microtitre plate, where:
(i) for each assay providing in a well of said microtitre plate
(a) a solution comprising said nickel;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to said nickel wherein said cytokine is selected from the group consisting of IL-4, IL-5, and IL-13;
(ii) for each assay contacting said T-cells with said nickel, said antigen presenting cells and said surface under conditions which are suitable for
(a) release of said cytokine by said T-cells that have been presensitized in vivo to said nickel; and
(b) binding of said cytokine to said first antibody to form a cytokine/antibody complex;
(iii) for each assay detecting binding of said cytokine to said first antibody by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting said cytokine, thereby detecting cytokine release by said T-cells at the specific T-cell level and hence whether said subject has said allergy against nickel, where said spots are enumerated using a second antibody which is labeled and which specifically binds to said cytokine; and
(iv) comparing the results of (iii) with those of a control performed without said nickel, where if the number of cytokine releasing T-cells is greater in (iii) than for the control for at least one said cytokine, the subject is determined to have an allergy against nickel.

### Claim 10 (depends on 1)

A method according to claim 1, where the surface is a polyvinylidene difluoride membrane.

### Claim 11 (depends on 6)

A method according to claim 6, where the surface is a polyvinylidene difluoride membrane.

### Claim 12 (depends on 7)

A method according to claim 7, where the surface is a polyvinylidene difluoride membrane.

### Claim 13 (depends on 8)

A method according to claim 8, where the surface is a polyvinylidene difluoride membrane.

### Claim 14 (depends on 9)

A method according to claim 9, where the surface is a polyvinylidene difluoride membrane.

### Claim 15

An in vitro method for diagnosing an allergy, where the allergy is caused by contact of the skin of a subject with nickel, which method comprises:
(i) providing
(a) a NiCl2 solution;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to said NiCl2 solution wherein said cytokine is selected from the group consisting of IL-4, IL-5, and IL-13;
(ii) contacting said T-cells with said NiCl2 solution, said antigen presenting cells and said surface under conditions which are suitable for
(a) release of said cytokine by said T-cells that have been presensitized in vivo to said nickel; and
(b) binding of said cytokine to said first antibody, to form a cytokine/antibody complex; and
(iii) detecting binding of said cytokine to said first antibody by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting said cytokine, said detection performed by using a labeled second antibody which binds to a cytokine selected from the group consisting of IL-4, IL-5 and IL-13 and quantifying spots of said cytokine/antibody complex, thereby detecting any nickel-specific T-cells at the single cell level and hence allergy caused by the contact of the skin to nickel.

### Claim 16

An in vitro method for diagnosing nickel allergy in a subject, which method comprises:
(i) providing
(a) NiCl2;
(b) T-cells from said subject;
(c) antigen presenting cells; and
(d) a surface to which is immobilized a first antibody capable of specifically binding to a cytokine released from said T-cells in response to NiCl2, wherein said cytokine is selected from the group consisting of IL-4, IL-5 and IL-13;
(ii) contacting said T-cells with said NiCl2, said antigen presenting cells and said surface under conditions which are suitable for
(a) release of said cytokine by T-cells that have been presensitized in vivo to nickel by contact with the skin; and
(b) binding of said cytokine to said first antibody to form a cytokine/antibody complex;
(iii) detecting binding of said cytokine to said first antibody by enumerating spots of said cytokine/antibody complex formed on the surface, where each spot represents a T-cell which is secreting the cytokine, said detection performed by using a labeled second antibody which binds to a cytokine selected from the group consisting of IL-4, IL-5 and IL-13 and quantifying spots of said cytokine/antibody complex, thereby detecting nickel-specific T-cells at the single cell level; and
(iv) comparing the results of (iii) with those of a control performed without said NiCl2, where if the number of cytokine releasing T-cells is greater in (iii) than for the control for at least one said cytokine, the subject is determined to have an allergy to said nickel.

### Claim 17 (depends on 1)

A method according to claim 1 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.

### Claim 18 (depends on 6)

A method according to claim 6 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.

### Claim 19 (depends on 7)

A method according to claim 7 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.

### Claim 20 (depends on 8)

A method according to claim 8 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.

### Claim 21 (depends on 9)

A method according to claim 9 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.

### Claim 22 (depends on 15)

A method according to claim 15 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.

### Claim 23 (depends on 16)

A method according to claim 16 wherein said T-cells from said subject and said antigen presenting cells are provided in the form of a sample of peripheral blood mononuclear cells (PBMCs) from said subject.
